TransCode Therapeutics, Inc. announced a co-research agreement with Debiopharm. The collaboration will explore combining TransCode?s proprietary TTX delivery platform with Debiopharm?s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer. TransCode?s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics.

TransCode has developed and tested the TTX platform for the delivery of various nucleic acid therapeutics to cancer cells, including small interfering RNAs, antisense oligonucleotides, immunostimulatory oligonucleotides, mRNA, and genome-editing ribonucleoprotein complexes (CRISPR). TransCode?s lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial. As part of the collaboration, TransCode will combine its TTX delivery platform with Debiopharm?s proprietary technologies to generate constructs designed to provide targeted mRNA delivery to cancer cells.

Under the agreement, these constructs will be tested both in cancer cells and in tumor-bearing animals. Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities. Debiopharm?s ongoing quest towards developing highly innovative drug delivery methods is based on the recognition that novel targeted medicines hold the potential to revolutionize cancer research and treatment by improving precision, efficacy, safety, and the overall therapeutic outcome for cancer patients.

The company hopes that future advancements could usher in a new era of more effective and personalized cancer therapies.